- Excellent activity against MDR P. aeruginosa, A.baumannii & K. pneumoniae.
- Combination therapy shows high synergy rates with carbapenem in MDR Gram negative pathogen with less resistance.
- Combination of Doripenem with Colistin yields greater decrease in MPC/MIC ratio than combination with Meropenem.
- Carbapenem resistant K. pneumoniae isolates found to be susceptible to Colistin.
- Loading dose of 6 MIU to 9 MIU is clinic proven to enhance bacterial eradication in critical ill patients.